Kennedy Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.3M Buy
484,580
+50,814
+12% +$3.58M 0.66% 18
2025
Q4
$29.2M Buy
433,766
+50,209
+13% +$3.38M 0.62% 17
2025
Q3
$28.1M Sell
383,557
-31,719
-8% -$2.11M 0.62% 17
2025
Q2
$21.6M Sell
415,276
-59,177
-12% -$3.37M 0.52% 31
2025
Q1
$30.3M Buy
474,453
+80,427
+20% +$4.67M 0.72% 12
2024
Q4
$18.8M Buy
394,026
+29,484
+8% +$1.51M 0.42% 42
2024
Q3
$20.9M Sell
364,542
-77,153
-17% -$4.42M 0.46% 31
2024
Q2
$23.1M Sell
441,695
-71,401
-14% -$3.13M 0.49% 29
2024
Q1
$20.9M Sell
513,096
-149,720
-23% -$5.61M 0.43% 40
2023
Q4
$24.5M Buy
662,816
+16,341
+3% +$615K 0.54% 21
2023
Q3
$24.7M Buy
646,475
+28,880
+5% +$1.18M 0.6% 15
2023
Q2
$22.3M Buy
617,595
+113,886
+23% +$3.89M 0.52% 26
2023
Q1
$19.2M Sell
503,709
-70,485
-12% -$3.31M 0.57% 20
2022
Q4
$32.7M Sell
574,194
-71,579
-11% -$3.66M 0.92% 1
2022
Q3
$25.5M Buy
645,773
+43,762
+7% +$1.93M 0.75% 8
2022
Q2
$26.5M Buy
602,011
+39,961
+7% +$1.73M 0.74% 7
2022
Q1
$22.4M Buy
562,050
+22,308
+4% +$795K 0.53% 29
2021
Q4
$21.7M Sell
539,742
-8,841
-2% -$330K 0.46% 39
2021
Q3
$22.3M Buy
548,583
+195,504
+55% +$8.17M 0.5% 24
2021
Q2
$16M Sell
353,079
-2,398
-0.7% -$106K 0.34% 70
2021
Q1
$14.8M Buy
355,477
+23,021
+7% +$1.05M 0.3% 90
2020
Q4
$14.2M Sell
332,456
-1,849
-0.6% -$66.5K 0.32% 81
2020
Q3
$8.79M Sell
334,305
-2,254
-0.7% -$62.8K 0.25% 117
2020
Q2
$9.02M Sell
336,559
-6,982
-2% -$158K 0.26% 108
2020
Q1
$6.18M Buy
343,541
+113,253
+49% +$2.15M 0.23% 137
2019
Q4
$4.08M Buy
230,288
+62,942
+38% +$1.09M 0.1% 392
2019
Q3
$2.6M Sell
167,346
-10,174
-6% -$168K 0.06% 491
2019
Q2
$3.05M Sell
177,520
-141
-0.1% -$2.27K 0.07% 468
2019
Q1
$2.86M Sell
177,661
-58,405
-25% -$946K 0.07% 481
2018
Q4
$3.45M Sell
236,066
-358,468
-60% -$5.72M 0.09% 428
2018
Q3
$10.8M Sell
594,534
-13,655
-2% -$239K 0.2% 155
2018
Q2
$10.3M Buy
608,189
+93,544
+18% +$1.77M 0.19% 152
2018
Q1
$10.1M Buy
514,645
+6,667
+1% +$129K 0.2% 149
2017
Q4
$10.3M Sell
507,978
-57,551
-10% -$1.06M 0.18% 167
2017
Q3
$9.82M Buy
565,529
+19,329
+4% +$262K 0.18% 181
2017
Q2
$7M Sell
546,200
-150,245
-22% -$2.01M 0.13% 264
2017
Q1
$9.03M Sell
696,445
-3,284
-0.5% -$41.5K 0.16% 218
2016
Q4
$6.91M Buy
699,729
+161,186
+30% +$1.77M 0.12% 294
2016
Q3
$6.51M Buy
538,543
+417,498
+345% +$4.27M 0.12% 292
2016
Q2
$1.04M Buy
121,045
+47,364
+64% +$467K 0.02% 646
2016
Q1
$698K Buy
73,681
+2,818
+4% +$26.5K 0.01% 680
2015
Q4
$1.23M Buy
70,863
+22,539
+47% +$359K 0.02% 637
2015
Q3
$649K Buy
48,324
+1,157
+2% +$23.2K 0.01% 679
2015
Q2
$1.06M Buy
+47,167
New +$829K 0.02% 665

Other funds holding HALO

Kennedy Capital Management's HALO Position: Q1 2026 in Review

Kennedy Capital Management increased its Halozyme (HALO) stake by 12% in Q1 2026, buying an estimated $3.58M and bringing the position to 484,580 shares worth $31.3M. The position accounts for 0.66% of the portfolio, ranked #18.

Kennedy Capital Management first reported a position in HALO in Q2 2015 and has held it in 44 quarters since. The position peaked at $32.7M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Kennedy Capital Management held 484,580 shares of Halozyme worth $31.3M as of Q1 2026.
  • Kennedy Capital Management bought 50,814 Halozyme shares in Q1 2026, an estimated $3.58M.
  • Halozyme made up 0.66% of Kennedy Capital Management's portfolio in Q1 2026, its #18 holding.
  • Kennedy Capital Management first reported a position in Halozyme in Q2 2015 and has held it in 44 quarters since.
  • Kennedy Capital Management's Halozyme position peaked at $32.7M in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.